Cargando…

PPARs in Alzheimer's Disease

Peroxisome proliferator-activated receptors (PPARs) are well studied for their peripheral physiological and pathological impact, but they also play an important role for the pathogenesis of various disorders of the central nervous system (CNS) like multiple sclerosis, amyotrophic lateral sclerosis,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kummer, Markus P., Heneka, Michael T.
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2008
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2465016/ https://www.ncbi.nlm.nih.gov/pubmed/18645613 http://dx.doi.org/10.1155/2008/403896

Ejemplares similares

Impact and Therapeutic Potential of PPARs in Alzheimer's Disease
por: Heneka, Michael T, et al.
Publicado: (2011)

Body Fluid Cytokine Levels in Mild Cognitive Impairment and Alzheimer’s Disease: a Comparative Overview
por: Brosseron, Frederic, et al.
Publicado: (2014)

Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease
por: Chalermpalanupap, Termpanit, et al.
Publicado: (2013)

Truncated and modified amyloid-beta species
por: Kummer, Markus P, et al.
Publicado: (2014)

Pan-PPAR Modulation Effectively Protects APP/PS1 Mice from Amyloid Deposition and Cognitive Deficits
por: Kummer, Markus P., et al.
Publicado: (2014)

Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer’s disease
por: Brosseron, Frederic, et al.
Publicado: (2018)

Peroxisome Proliferator-Activated Receptors (PPARs) as Potential Inducers of Antineoplastic Effects in CNS Tumors
por: Tatenhorst, Lars, et al.
Publicado: (2008)

The Contribution of the Locus Coeruleus–Noradrenaline System Degeneration during the Progression of Alzheimer’s Disease
por: Mercan, Dilek, et al.
Publicado: (2022)

Microglial PD‐1 stimulation by astrocytic PD‐L1 suppresses neuroinflammation and Alzheimer’s disease pathology
por: Kummer, Markus P, et al.
Publicado: (2021)

Microglia in Alzheimer’s disease: Local heroes!
por: Villacampa, Nàdia, et al.
Publicado: (2020)

PPAR Gamma Activators: Off-Target Against Glioma Cell Migration and Brain Invasion
por: Seufert, Sebastian, et al.
Publicado: (2008)

Signaling Mechanisms of Selective PPARγ Modulators in Alzheimer's Disease
por: Govindarajulu, Manoj, et al.
Publicado: (2018)

NLRP3 is activated in Alzheimer´s disease and contributes to pathology in APP/PS1 mice
por: Heneka, Michael T., et al.
Publicado: (2012)

Selective PPAR-Delta/PPAR-Gamma Activation Improves Cognition in a Model of Alzheimer’s Disease
por: Steinke, Ian, et al.
Publicado: (2023)

The role of peripheral inflammatory insults in Alzheimer’s disease: a review and research roadmap
por: Walker, Keenan A., et al.
Publicado: (2023)

Therapeutic Advantages of Dual Targeting of PPAR-δ and PPAR-γ in an Experimental Model of Sporadic Alzheimer’s Disease
por: Reich, D, et al.
Publicado: (2018)

Infection and inflammation: New perspectives on Alzheimer's disease
por: Whitson, Heather E., et al.
Publicado: (2022)

Emerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases
por: Kulkarni, Ajit A., et al.
Publicado: (2012)

The Novel Role of PPAR Alpha in the Brain: Promising Target in Therapy of Alzheimer’s Disease and Other Neurodegenerative Disorders
por: Wójtowicz, Sylwia, et al.
Publicado: (2020)

Peripheral and central immune system crosstalk in Alzheimer disease — a research prospectus
por: Bettcher, Brianne M., et al.
Publicado: (2021)

Distinct modulation of microglial amyloid β phagocytosis and migration by neuropeptides(i)
por: Fleisher-Berkovich, Sigal, et al.
Publicado: (2010)

Publisher Correction: Peripheral and central immune system crosstalk in Alzheimer disease — a research prospectus
por: Bettcher, Brianne M., et al.
Publicado: (2021)

Aβ Oligomer Toxicity-Reducing Therapy for the Prevention of Alzheimer’s Disease: Importance of the Nrf2 and PPARγ Pathways
por: Araki, Wataru
Publicado: (2023)

PPAR Agonists and Cardiovascular Disease in Diabetes
por: Calkin, Anna C., et al.
Publicado: (2008)

PPARγ in Inflammatory Bowel Disease
por: Annese, Vito, et al.
Publicado: (2012)

PPARs, Obesity, and Inflammation
por: Stienstra, Rinke, et al.
Publicado: (2007)

Proteome profiling of s-nitrosylated synaptosomal proteins by isobaric mass tags
por: Wijasa, Teodora Stella, et al.
Publicado: (2017)

Impact of COVID‐19 on the Onset and Progression of Alzheimer's Disease and Related Dementias: A Roadmap for Future Research
por: Gordon, Marcia N., et al.
Publicado: (2021)

Early Changes in Hippocampal Neurogenesis in Transgenic Mouse Models for Alzheimer’s Disease
por: Unger, M. S., et al.
Publicado: (2016)

Update on Pparγ and Nonalcoholic Fatty Liver Disease
por: Ables, Gene P.
Publicado: (2012)

Probing the role of PPARγ in the regulation of late-onset Alzheimer’s disease-associated genes
por: Barrera, Julio, et al.
Publicado: (2018)

Regulation of PPARα by APP in Alzheimer disease affects the pharmacological modulation of synaptic activity
por: Sáez-Orellana, Francisco, et al.
Publicado: (2021)

Imaging noradrenergic influence on amyloid pathology in mouse models of Alzheimer’s disease
por: Winkeler, A., et al.
Publicado: (2008)

PPARγ and PPARδ as Modulators of Neoplasia and Cell Fate
por: Glazer, Robert I., et al.
Publicado: (2008)

Targeting Neuroinflammation to Treat Alzheimer’s Disease
por: Ardura-Fabregat, A., et al.
Publicado: (2017)

PPAR Genomics and Pharmacogenomics: Implications for Cardiovascular Disease
por: Cresci, Sharon
Publicado: (2008)

PPAR Regulation of Inflammatory Signaling in CNS Diseases
por: Bright, John J., et al.
Publicado: (2008)

Therapeutic Implications of PPARγ in Cardiovascular Diseases
por: Hasegawa, Hiroshi, et al.
Publicado: (2010)

PPAR Medicines and Human Disease: The ABCs of It All
por: Apostoli, Anthony J., et al.
Publicado: (2012)

PPARγ and Its Role in Cardiovascular Diseases
por: Chandra, Mini, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0d0r69iu2iajkkrgfc4folc5iu